Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma: A phase II trial
Autore:
Tetef, M; Leong, L; Ahn, C; Akman, S; Chow, W; Margolin, K; Morgan, RJ; Raschko, J; Shibata, S; Somlo, G; Doroshow, JH;
Indirizzi:
City Hope Natl Med Ctr, Dept Biostat, Duarte, CA 91010 USA City Hope Natl Med Ctr Duarte CA USA 91010 Biostat, Duarte, CA 91010 USA CityAHope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA 91010 US City Hope Natl Med Ctr Duarte CA USA 91010 apeut Res, Duarte, CA 91010 US
Titolo Testata:
CANCER INVESTIGATION
fascicolo: 2, volume: 17, anno: 1999,
pagine: 114 - 117
SICI:
0735-7907(1999)17:2<114:CAICAF>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
COMBINATION CHEMOTHERAPY; 1-BETA-D-ARABINOFURANOSYLCYTOSINE; CIS-DIAMMINEDICHLOROPLATINUM(II); INVITRO; HYDROXYUREA; PLATINUM; SYNERGY;
Keywords:
colon carcinoma; rectal carcinoma; phase II trial; cisplatin; cytosine arabinoside;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
12
Recensione:
Indirizzi per estratti:
Indirizzo: Tetef, M CityUSApe Natl Med Ctr, Dept Med Oncol, 1500 E Duarte Rd, Duarte,CA 91010 City Hope Natl Med Ctr 1500 E Duarte Rd Duarte CA USA 91010 91010
Citazione:
M. Tetef et al., "Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma: A phase II trial", CANCER INV, 17(2), 1999, pp. 114-117

Abstract

Based on the in vitro and in vivo synergy between cytosine arabinoside (Ara-C) and cis-diamminedichloroplatinum (cisplatin), we designed a phase II trial of Ara-C with cisplatin for patients with colorectal adenocarcinoma. Forty-eight eligible patients received continuous infusion Ara-C, 30 mg/m(2)/day over 72 hr, plus cisplatin, 30 mg/m(2) for three doses at hours 12, 36, and 50 of the Ara-C infusion. The objective partial response rate for patients with colon carcinoma was 3% (1/32 patients; 95% CI, 0-16%) with a median response duration of 2.8 months. None of the 16 patients treated for rectal carcinoma responded. Myelosuppression was the most severe toxicity. Significant gastrointestinal and hepatic toxicities occurred in a small number of patients. Nephrotoxicity and neurotoxicity were mild. We conclude thatthe prolonged infusion of Ara-C in combination with divided closes of cisplatin offers no significant therapeutic advantage.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/04/20 alle ore 05:22:44